Epigenetic modulation as a therapy in systemic sclerosis

Steven O'Reilly

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


SSc is an autoimmune idiopathic disease in which there is an inflammatory component driving fibrosis. The chief cell involved is the myofibroblast, which when activated secretes copious amounts of extracellular matrix that forms deposits, leading to stiffness and fibrosis. The fibrosis is most prevalent in the skin and lungs. In recent years epigenetic modifications have been uncovered that positively and negatively regulate the genesis of the myofibroblasts and that can be activated and regulated by a variety of cytokines and hormones. The epigenetic contribution to these cells and to SSc is only now really coming to light, and this opens up a new therapeutic target for the disease for which many epigenetic drugs, such as miRNA replacements, are beginning to be developed. This review will examine the epigenetic regulators in the disease and possible targeting of these.

Original languageEnglish
Pages (from-to)191-196
Number of pages6
JournalRheumatology (Oxford, England)
Issue number2
Early online date22 Mar 2018
Publication statusPublished - 1 Feb 2019


Dive into the research topics of 'Epigenetic modulation as a therapy in systemic sclerosis'. Together they form a unique fingerprint.

Cite this